Fiasp Cartridges contains 3 mL of 100 units/mL solution for injection, and cartons containing five units are available. Refillable PenFill cartridge devices such as Fiasp FlexTouch are exclusively compatible with Fiasp Cartridges. Ensure you are ordering the correct cartridges, as Flextouch pens can come in different forms including (Novolin Flextouch and cartridges).
Insulin aspart is a fast-acting human form of insulin that effectively lowers blood sugar levels for type 1 and type 2 diabetes patients.
Two expedients added to the formulation include Vitamin B3 (niacinamide) and L-arginine. This is to increase the speed of absorption faster and stability when compared to other mealtime insulin’s. It works almost immediately after application.
Typically this insulin is paired with longer-acting insulin types (basal insulin) that work throughout the day (between meals and while you sleep).
Fiasp is a fast-acting mealtime insulin aspart formulation used to treat diabetes. Fiasp will start to lower your blood sugar within 20 minutes after starting a meal. Due to this fast action, Fiasp should typically be combined with intermediate- or long-acting insulin preparation.
Cartons of 5 units are available. Each Fiasp cartridge contains 3mL of 100 units/mL solution for injection. Fiasp is also available in vial form.
Initiation
Patients with type 1 diabetes mellitus
The recommended starting dose in insulin naïve patients with type 1 diabetes is approximately 50% of the total daily insulin dose and should be divided between the meals based on the size and composition of the meals. The remainder of the total daily insulin dose should be administered as intermediate-acting or long-acting insulin. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin naïve patients with type 1 diabetes.
Patients with type 2 diabetes mellitus
Suggested initial dose is 4 units at one or more meals. Number of injections and subsequent titration will depend on the individual glycaemic target and the size and composition of the meals.
Dose adjustment may be considered daily based on self-measured plasma glucose (SMPG) on the previous day(s) according to Table 1.